Indevus Pharmaceuticals, Inc. (Indevus) is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company’s products include SANCTURA and SANCTURA XR for overactive bladder (OAB), which it co-promotes with its partner Allergan, Inc. (Allergan); VANTAS for advanced prostate cancer; SUPPRELIN LA for central precocious puberty (CPP), and DELATESTRYL for the treatment of hypogonadism. Its advanced compounds are VALSTAR for bladder cancer, NEBIDO for hypogonadism, PRO 2000 for the prevention of infection by human immunodeficiency virus (HIV) and other sexually transmitted pathogens, and the octreotide implant for acromegaly and carcinoid syndrome. In March 2009, Endo Pharmaceuticals Holdings Inc. completed the acquisition of Indevus.